OssDsign Shifts to Pure Play Orthobiologics

OssDsign is undertaking a strategic shift to focus operations on its orthobiologics business in the U.S.

The company will focus on its nanosynthetic bone graft OssDsign Catalyst, an off-the-shelf product characterized by high scalability. All activities pertaining to the company’s OssDsign Cranial PSI patient-specific cranial implant business...

document icon

You’ve reached your limit.

We’re glad you’re finding value in our content — and we’d love for you to keep going.

Subscribe now for unlimited access to orthopedic business intelligence.

JV

Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.



Contact Us

0